09:00 – 09:20
Kaufmann W. (Harvard Med. School, USA): The lessons from IGF-1 trials.
09:20 – 09:40
Glaze D. (Texas, USA): NNZ-2566: a novel, experimental treatment.
09:40 – 10:00
Djukic A. (New York, USA): Pharmacological treatments with Copaxone and Statins.
10:00 – 10:20
Ben Zeev B. (Tel Aviv, Israel): Copaxone from cells to RTT patients -hopes and unexpected adverse events.
10:20 – 10:40
Discussion
10:40 – 11:00
Coffee Break
11:00 – 11:20
Mancini J. (Marseille, France): Desipramine and cardio-respiratory variability.
11:20 – 11:40
Rothenbuhler A. (Paris, France): Bone Health in Rett Syndrome.
11:40 – 12:00
Hayek J. (Siena): EPI-743 trial results.
12:00 – 12:10
Discussion
Moderators: Villard L., Clarke A.
ABSTRACT:
The Treatment of Rett Syndrome with NNZ-2566 (trofinetide)